Summary
6-MAPB, chemically known as 1-(benzofuran-6-yl)-N-methylpropan-2-amine, is a substance known for its psychedelic and entactogenic properties. It shares a structural resemblance with both 6-APB and MDMA, established through multiple references.
While not widely recognized as a “designer drug,” 6-MAPB has been identified in analytical samples obtained from individuals who required hospitalization due to the use of drug combinations containing other benzofuran derivatives. However, specific citations are needed for verification.
The United Kingdom implemented a ban on 6-MAPB in June 2013, along with nine other closely related compounds believed to elicit similar effects, underlining concerns about their safety and potential for misuse.
| Identifiers | |
|---|---|
| IUPAC name | |
| CAS Number | 1354631-79-0 |
|---|---|
| PubChem CID | 122202866 |
| ChemSpider | 32078890 |
| UNII | 4J6PD2FN87 |
| Chemical and physical data | |
| Formula | C12H15NO |
| Molar mass | 189.258 g·mol−1 |
FAQ
1. What is 6-MAPB?
6-MAPB is a chemical compound, specifically 1-(benzofuran-6-yl)-N-methylpropan-2-amine, known for its psychedelic and entactogenic effects. It bears structural similarities to 6-APB and MDMA.
2. Is 6-MAPB legal to use?
The legal status of 6-MAPB can vary from one region to another. It’s essential to check the laws and regulations in your specific area to determine its legality.
3. What are the potential effects of 6-MAPB?
6-MAPB is known for its psychedelic and entactogenic properties. These effects can vary from person to person and depend on factors such as dosage and individual tolerance.
4. Is 6-MAPB safe to use?
The safety of 6-MAPB is not well-documented due to limited research. Using substances with unclear safety profiles can be risky, and its use is generally discouraged.
5. Can 6-MAPB be detected in drug tests?
The detectability of 6-MAPB in drug tests may depend on the specific test being administered. To avoid potential legal and employment issues, it’s best to avoid substances with uncertain legal status.
6. What are the potential side effects or risks associated with 6-MAPB?
Due to the limited research on 6-MAPB, the potential risks and side effects need to be well-established. Using such substances carries inherent uncertainties and should be approached with caution.
7. Is there harm reduction advice for using 6-MAPB safely?
Harm reduction strategies are essential when dealing with psychoactive substances. It’s crucial to prioritize safety, responsible use, and informed decision-making. Seek guidance from harm reduction organizations or healthcare professionals for advice on minimizing risks when using substances like 6-MAPB.
8. Where can I find more information about 6-MAPB?
For reliable information on 6-MAPB and similar compounds, consult reputable sources, scientific literature, government health agencies, and harm reduction organizations.
9. What should I do if I suspect someone is using 6-MAPB or a similar designer drug?
If you suspect someone is using designer drugs or facing substance abuse issues, encourage them to seek professional help and support. Reach out to healthcare providers, counselors, or addiction specialists for guidance.
10. Has 6-MAPB been banned in any countries?
Yes, 6-MAPB has been banned in some countries, including the United Kingdom, where it was prohibited in June 2013. Regulations regarding its legality can change over time and by location, so it’s essential to stay informed about its current status.
References
- Welter J, Brandt SD, Kavanagh P, Meyer MR, Maurer HH (May 2015). “Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS(n) techniques” (PDF). Analytical and Bioanalytical Chemistry. 407 (12): 3457–3470. doi:10.1007/s00216-015-8552-2. PMID 25711990. S2CID 5475974.In May 2015, a significant study led by Welter and colleagues delved into the metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of benzofuran designer drugs, specifically 6-APB and 6-MAPB. This research compared these compounds to their 5-isomers using advanced analytical techniques.
- Welter-Luedeke J, Maurer HH (February 2016). “New Psychoactive Substances: Chemistry, Pharmacology, Metabolism, and Detectability of Amphetamine Derivatives With Modified Ring Systems”. Therapeutic Drug Monitoring. 38 (1): 4–11. doi:10.1097/FTD.0000000000000240. PMID 26327309. S2CID 20737913.In February 2016, Welter-Luedeke and Maurer explored the realm of new psychoactive substances, particularly amphetamine derivatives with modified ring systems. This research investigated their chemistry, pharmacology, metabolism, and detectability.
- Shimshoni JA, Winkler I, Golan E, Nutt D (January 2017). “Neurochemical binding profiles of novel indole and benzofuran MDMA analogues”. Naunyn-Schmiedeberg’s Archives of Pharmacology. 390 (1): 15–24. doi:10.1007/s00210-016-1297-4. PMID 27650729. S2CID 253741131.In January 2017, Shimshoni and collaborators delved into the neurochemical binding profiles of novel indole and benzofuran MDMA analogues. This research examined how these compounds interact with neurochemical systems.
- Brandt SD, Walters HM, Partilla JS, Blough BE, Kavanagh PV, Baumann MH (December 2020). “The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats”. Psychopharmacology. 237 (12): 3703–3714. doi:10.1007/s00213-020-05648-z. PMC 7686291. PMID 32875347.In December 2020, Brandt and colleagues investigated the psychoactive effects of aminoalkylbenzofuran derivatives, specifically 5-APB and 6-APB, and their resemblance to the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats.
- “Temporary class drug order report on 5-6APB and NBOMe compounds”. UK Home Office. 4 Jun 2013. Retrieved 2013-07-10.On June 4, 2013, the UK Home Office issued a temporary class drug order report addressing 5-6APB and NBOMe compounds. This report sheds light on regulatory actions taken concerning these substances during that time.